Clinical Lung Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of lung cancer. Clinical Lung Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of lung cancer. The main emphasis is on recent scientific developments in all areas related to lung cancer. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.
《临床肺癌》是一份同行评审的双月刊杂志，发表描述肺癌临床和转化研究各个方面的原创文章。《临床肺癌》致力于肺癌的检测、诊断、预防和治疗方面的文章。主要重点是最近在与肺癌有关的所有领域的科学发展。感兴趣的具体领域包括临床研究和机械方法;药物敏感性和耐药性;基因和反义治疗;病理学、标志物和预后指标;化学预防策略;综合疗法;以及各种方法的综合。
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients.
来源期刊：Clinical lung cancerDOI：10.1016/j.cllc.2019.02.006
Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
来源期刊：Clinical lung cancerDOI：10.1016/j.cllc.2018.10.002
Adjuvant Therapy in Patients With Completely Resected Non–small‐cell Lung Cancer: Current Status and Perspectives
来源期刊：Clinical Lung CancerDOI：10.1016/j.cllc.2018.09.016
Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations
来源期刊：Clinical Lung CancerDOI：10.1016/j.cllc.2018.11.005
Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors.
来源期刊：Clinical lung cancerDOI：10.1016/J.CLLC.2019.07.006
Clinical Features and Prognosis of Pulmonary Lymphoepithelioma-like Carcinoma: Summary of Eighty-five Cases.
来源期刊：Clinical lung cancerDOI：10.1016/j.cllc.2018.12.014
Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non-small-cell Lung Cancer: Implications of FISH-positive Patterns.
来源期刊：Clinical lung cancerDOI：10.1016/j.cllc.2019.02.008
Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring Epidermal Growth Factor Receptor Mutations
来源期刊：Clinical Lung CancerDOI：10.1016/j.cllc.2018.09.010
Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer Patients.
来源期刊：Clinical lung cancerDOI：10.1016/j.cllc.2019.06.020
Cancer Stem Cell Biomarkers in EGFR-Mutation-Positive Non-Small-Cell Lung Cancer.
来源期刊：Clinical lung cancerDOI：10.1016/j.cllc.2019.02.005
Heterogeneous Expression of Programmed Death Receptor-ligand 1 on Circulating Tumor Cells in Patients With Lung Cancer.
来源期刊：Clinical lung cancerDOI：10.1016/J.CLLC.2019.03.004
Perspectives: Neutrophil-to-lymphocyte Ratio as a Potential Biomarker in Immune Checkpoint Inhibitor for Non-Small-Cell Lung Cancer.
来源期刊：Clinical lung cancerDOI：10.1016/J.CLLC.2018.12.003
Perceptions and Utilization of Lung Cancer Screening Among Smokers Enrolled in a Tobacco Cessation Program
来源期刊：Clinical Lung CancerDOI：10.1016/j.cllc.2018.09.013
Blood Predictive Biomarkers for Patients With Non-small-cell Lung Cancer Associated With Clinical Response to Nivolumab.
来源期刊：Clinical lung cancerDOI：10.1016/j.cllc.2019.08.006
Significance of 18F‐FDG PET Parameters According to Histologic Subtype in the Treatment Outcome of Stage III Non–small‐cell Lung Cancer Undergoing Definitive Concurrent Chemoradiotherapy
来源期刊：Clinical Lung CancerDOI：10.1016/j.cllc.2018.08.018
Lymph Node Size Predicts for Asymptomatic Brain Metastases in Patients With Non–small‐cell Lung Cancer at Diagnosis
来源期刊：Clinical Lung CancerDOI：10.1016/j.cllc.2018.09.014
Monitoring Treatment Response to Erlotinib in EGFR‐mutated Non–small‐cell Lung Cancer Brain Metastases Using Serial O‐(2‐[18F]fluoroethyl)‐L‐tyrosine PET
来源期刊：Clinical Lung CancerDOI：10.1016/j.cllc.2018.10.011
Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy.
来源期刊：Clinical lung cancerDOI：10.1016/J.CLLC.2019.07.009
Identification and Development of a Lung Adenocarcinoma PDX Model With STRN‐ALK Fusion
来源期刊：Clinical Lung CancerDOI：10.1016/j.cllc.2018.11.002
Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice.
来源期刊：Clinical lung cancerDOI：10.1016/J.CLLC.2019.02.013
Successful Treatment of a Patient With NSCLC Harboring an EGFR Mutation and a Concomitant Met Exon 14 Skipping Mutation Combining Afatinib and Crizotinib
来源期刊：Clinical Lung CancerDOI：10.1016/j.cllc.2018.09.009
Preselection of Lung Cancer Cases Using FGFR1 mRNA and Gene Copy Number for Treatment With Ponatinib
来源期刊：Clinical Lung CancerDOI：10.1016/j.cllc.2018.09.001
Impact of EGFR Mutation and ALK Translocation on Recurrence Pattern After Definitive Chemoradiotherapy for Inoperable Stage III Non-squamous Non-small-cell Lung Cancer.
来源期刊：Clinical lung cancerDOI：10.1016/J.CLLC.2019.02.021
High Receipt of Statins Reduces the Risk of Lung Cancer in Current Smokers With Hypercholesterolemia: The National Health Insurance Service–Health Screening Cohort
来源期刊：Clinical Lung CancerDOI：10.1016/j.cllc.2018.11.009
Incorporation of the SUVmax Measured From FDG PET and Neutrophil-to-lymphocyte Ratio Improves Prediction of Clinical Outcomes in Patients With Locally Advanced Non-small-cell Lung Cancer.
来源期刊：Clinical lung cancerDOI：10.1016/j.cllc.2019.06.008
Influence of Sociodemographic Factors on Treatment Decisions in Non-Small-Cell Lung Cancer.
来源期刊：Clinical lung cancerDOI：10.1016/j.cllc.2019.08.005
EGFR Gene Polymorphism Predicts Improved Outcome in Patients With EGFR Mutation-positive Non-small cell Lung Cancer Treated With Erlotinib.
来源期刊：Clinical lung cancerDOI：10.1016/j.cllc.2019.02.011
Predictors of Nodal and Metastatic Failure in Early Stage Non-small-cell Lung Cancer After Stereotactic Body Radiation Therapy.
来源期刊：Clinical lung cancerDOI：10.1016/J.CLLC.2018.12.016
Chemotherapy and Radiation Versus Chemotherapy Alone for Elderly Patients With N3 Stage IIIB NSCLC.
来源期刊：Clinical lung cancerDOI：10.1016/J.CLLC.2019.04.003
Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer.
来源期刊：Clinical lung cancerDOI：10.1016/j.cllc.2019.03.005
Elevated Circulating Activin A Levels in Patients With Malignant Pleural Mesothelioma Are Related to Cancer Cachexia and Reduced Response to Platinum-based Chemotherapy.
来源期刊：Clinical lung cancerDOI：10.1016/j.cllc.2019.10.013
Clinical Characteristics, Molecular Phenotyping, and Management of Isolated Adrenal Metastases From Lung Cancer.
来源期刊：Clinical lung cancerDOI：10.1016/j.cllc.2019.06.003
A Phase II Study of Nivolumab in Patients With Advanced Non–small‐cell Lung Cancer who Responded to Prior PD‐1/L1 Inhibitors: West Japan Oncology Group 9616L (WJOG9616L)
来源期刊：Clinical Lung CancerDOI：10.1016/j.cllc.2018.12.001
Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer.
来源期刊：Clinical lung cancerDOI：10.1016/j.cllc.2019.11.008
Management of Central Nervous System Metastases in Patients With Advanced Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer During Crizotinib Treatment.
来源期刊：Clinical lung cancerDOI：10.1016/J.CLLC.2019.06.013
Pulmonary Carcinosarcoma: A Surveillance, Epidemiology, and End Results (SEER) Analysis.
来源期刊：Clinical lung cancerDOI：10.1016/J.CLLC.2019.07.001
Development and Validation of a 18F-FDG PET/CT-Based Clinical Prediction Model for Estimating Malignancy in Solid Pulmonary Nodules Based on a Population With High Prevalence of Malignancy.
来源期刊：Clinical lung cancerDOI：10.1016/J.CLLC.2019.07.014
Second Primary Non-Small-Cell Lung Cancer After Head and Neck Cancer: A Population-Based Study of Clinical and Pathologic Characteristics and Survival Outcomes in 3597 Patients.
来源期刊：Clinical lung cancerDOI：10.1016/j.cllc.2019.02.017
Association Between Nicotine-dependent Gene Polymorphism and Smoking Cessation in Patients With Lung Cancer.
来源期刊：Clinical lung cancerDOI：10.1016/J.CLLC.2019.07.002
Clinical Impact of Rare and Compound Mutations of Epidermal Growth Factor Receptor in Patients With Non-Small-Cell Lung Cancer.
来源期刊：Clinical lung cancerDOI：10.1016/J.CLLC.2019.04.012
Occult Gastrointestinal Perforation in a Patient With EGFR-Mutant Non-Small-Cell Lung Cancer Receiving Combination Chemotherapy With Atezolizumab and Bevacizumab: Brief Report.
来源期刊：Clinical lung cancerDOI：10.1016/j.cllc.2019.11.014
Spirituality and Emotional Distress Among Lung Cancer Survivors.
来源期刊：Clinical lung cancerDOI：10.1016/J.CLLC.2019.06.015
Survival Disparities in Black Patients With EGFR-mutated Non-small-cell Lung Cancer.
来源期刊：Clinical lung cancerDOI：10.1016/J.CLLC.2019.07.003
Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Patients With Previously Untreated Advanced Non-Small-Cell Lung Cancer.
来源期刊：Clinical lung cancerDOI：10.1016/j.cllc.2018.11.012
Patient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Non-Small-Cell Lung Cancer in Clinical Practice.
来源期刊：Clinical lung cancerDOI：10.1016/j.cllc.2019.11.015
Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.
来源期刊：Clinical lung cancerDOI：10.1016/j.cllc.2019.10.010
Evidence That Established Lung Cancer Mortality Disparities in American Indians Are Not Due to Lung Cancer Genetic Testing and Targeted Therapy Disparities.
来源期刊：Clinical lung cancerDOI：10.1016/j.cllc.2019.10.012
The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma.
来源期刊：Clinical lung cancerDOI：10.1016/J.CLLC.2019.06.019
Increased Galectin-1 Expression in Thymic Epithelial Tumors.
来源期刊：Clinical lung cancerDOI：10.1016/j.cllc.2018.12.005
CT Volumetry and Basic Texture Analysis as Surrogate Markers in Advanced Non-small-cell Lung Cancer.
来源期刊：Clinical lung cancerDOI：10.1016/j.cllc.2019.08.004
